Skip to main content
Terug
IMNM logo

Immunome, Inc.

Datakwaliteit: 100%
IMNM
NASDAQ Healthcare Biotechnology
€ 20,21
▼ € 0,54 (-2,60%)
Marktkapitalisatie: 1,78B
Dagbereik
€ 19,91 € 21,17
52-Weeksbereik
€ 5,15 € 27,65
Volume
1.181.672
50D / 200D Gem.
€ 22,70 / € 15,69
Vorige Slotkoers
€ 20,75

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -8,4 0,3
P/B 2,8 2,9
ROE % -52,1 3,7
Net Margin % -3060,0 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 36,83 +82.2%
Low: € 32,00 High: € 40,00
Forward WPA
-€ 2,41
Omzet Sch.
4,4 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,36
-€ 0,14 – € 3,69
620 M 6
FY2029 -€ 0,06
-€ 0,16 – € 0,01
400 M 6
FY2028 -€ 1,18
-€ 2,86 – -€ 0,48
240 M 8

Belangrijkste Punten

Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -200,60M
PEG of 0,17 suggests growth is underpriced
Capital intensive — 139,53% of revenue goes to capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-23,23%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-52,09%
ROIC-25,16%
Net Margin-3059,99%
Op. Margin-3084,76%

Veiligheid

Debt / Equity
0,01
Current Ratio14,69
Interest Coverage0,00

Waardering

P/E Ratio
-8,36
P/B Ratio2,80
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -23,23% Revenue Growth (3Y) -29,63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6,94M Net Income (TTM) -212,39M
ROE -52,09% ROA -31,09%
Gross Margin 57,43% Operating Margin -3084,76%
Net Margin -3059,99% Free Cash Flow (TTM) -200,60M
ROIC -25,16% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 14,69
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -8,36 P/B Ratio 2,80
P/S Ratio 255,82 PEG Ratio 0,17
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,78B Enterprise Value 1,13B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6,94M 9,04M 14,02M 0,0 0,0
Net Income -212,39M -292,96M -106,81M -36,90M -24,71M
EPS (Diluted) -2,43 -5,00 -5,38 -3,09 -2,14
Gross Profit 3,99M 9,04M 14,02M 0,0 0,0
Operating Income -214,11M -305,80M -109,53M -36,90M -25,20M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 683,19M 240,24M 148,54M 24,05M 57,93M
Total Liabilities 48,85M 59,08M 28,66M 7,39M 9,74M
Shareholders' Equity 634,34M 181,17M 119,88M 16,65M 48,19M
Total Debt 3,86M 4,83M 1,65M 291.000,0 317.000,0
Cash & Equivalents 653,48M 143,35M 98,68M 20,32M 49,23M
Current Assets 660,78M 221,34M 144,70M 22,65M 56,64M
Current Liabilities 44,99M 54,31M 21,83M 7,33M 9,73M